• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    3/10/21 2:57:02 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care
    Get the next $BEAT alert in real time by email
    SC 13G/A 1 arrowmark-beat022621a2.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*



    BioTelemetry, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    090672106

    (CUSIP Number)

     

     

    February 28, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No. 090672106
     SCHEDULE 13G/A
    Page 2 of 6 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    ArrowMark Colorado Holdings, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware, United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0%
    12
    TYPE OF REPORTING PERSON
     
    IA

     

     
     

     

    CUSIP No.  090672106
     SCHEDULE 13G/A
    Page 3 of  6 Pages

     

    Item 1.(a) Name of Issuer

    BioTelemetry, Inc.

    (b) Address of Issuer’s Principal Executive Offices

    1000 Cedar Hollow Road

    Malvern, Pennsylvania 19355

    Item 2.(a) Name of Person Filing

    ArrowMark Colorado Holdings, LLC

    (b) Address of Principal Business Office, or, if none, Residence

    100 Fillmore Street, Suite 325

    Denver, Colorado 80206

    (c) Citizenship

    Please refer to Item 4 on each cover sheet for each filing person

     (d) Title of Class of Securities

    Common Stock, par value $0.001 per share

     (e) CUSIP No.:

    090672106

     
     

     

    CUSIP No.  090672106
     SCHEDULE 13G/A
    Page 4 of 6 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

     
     

     

    CUSIP No. 090672106
     SCHEDULE 13G/A
    Page 5 of 6 Pages

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount beneficially owned: 0

    (b) Percent of class: 0.0%

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not Applicable

     Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

      

     
     
    CUSIP No. 090672106
     SCHEDULE 13G/A
    Page 6 of 6 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: March 10, 2021

     

     

      ArrowMark Colorado Holdings, LLC
           
      By:  Richard Grove
        Name:  Richard Grove
        Title:  Chief Compliance Officer

     

     

     

     

     

     

     

    Get the next $BEAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BEAT

    DatePrice TargetRatingAnalyst
    7/14/2026$2.00Buy
    Maxim Group
    4/20/2026Buy → Hold
    D. Boral Capital
    3/31/2026$4.00Buy
    B. Riley Securities
    3/27/2026$5.00Buy
    D. Boral Capital
    3/16/2026$8.00Buy → Speculative Buy
    The Benchmark Company
    12/11/2025$8.00Speculative Buy → Buy
    The Benchmark Company
    12/8/2025$2.50Buy
    H.C. Wainwright
    10/31/2025$4.00Buy
    Roth Capital
    More analyst ratings

    $BEAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Ferrari Richard bought $46,000 worth of shares (57,500 units at $0.80), increasing direct ownership by 25% to 286,636 units (SEC Form 4)

    4/A - HeartBeam, Inc. (0001779372) (Issuer)

    4/24/26 4:05:03 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Director Ferrari Richard bought $50,000 worth of shares (29,412 units at $1.70), increasing direct ownership by 20% to 179,136 units (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    2/21/25 8:00:22 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    CFO Cruickshank Tim bought $30,000 worth of shares (17,647 units at $1.70) (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    2/21/25 7:55:14 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device

    Patent extends HeartBeam's ECG hardware platform with multi-modal sensing capabilities Acoustic sensors enable HeartBeam’s device to function as a "digital stethoscope" to assess heart valve function Thoracic impedance capability opens the door to heart failure monitoring without a surgical procedure HeartBeam now holds 26 issued patents worldwide, reflecting continued investment in building a durable IP moat around its platform HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the allowance of a new U.S. patent that significantly expands the capabilities of its credit card-si

    7/14/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule

    Accelerated enrollment completion in ALIGN-ASS study underscores HeartBeam’s execution on its key strategic priority of heart attack detectionData analysis is underway, with full results anticipated for presentation at upcoming cardiology conferenceFindings will inform the design of the planned U.S. pivotal study and support the FDA pathwayFuture indication expansion could unlock a large addressable market of millions of patients at riskHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through powerful cardiac insights, today announced completion of patient enrollment in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack

    6/30/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition

    Company will license its 3D ECG signal technology to established partners, moving beyond direct medical device sales Advancing toward heart attack detection as a key expansion of the platform Tailoring its technology to fit each market, while operating with a leaner, more focused structure Company to provide more details on strategy as part of Second Quarter 2026 conference call in August HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a reorganization to prioritize global market reach and capital efficiency while accelerating execution. The company has aligned its operation

    6/24/26 4:05:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Ferrari Richard bought $46,000 worth of shares (57,500 units at $0.80), increasing direct ownership by 25% to 286,636 units (SEC Form 4)

    4/A - HeartBeam, Inc. (0001779372) (Issuer)

    4/24/26 4:05:03 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Cruickshank Tim

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    4/16/26 8:48:21 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Elfrink Willem

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    4/16/26 8:48:07 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on HeartBeam with a new price target

    Maxim Group initiated coverage of HeartBeam with a rating of Buy and set a new price target of $2.00

    7/14/26 8:17:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam downgraded by D. Boral Capital

    D. Boral Capital downgraded HeartBeam from Buy to Hold

    4/20/26 8:06:13 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on HeartBeam with a new price target

    B. Riley Securities initiated coverage of HeartBeam with a rating of Buy and set a new price target of $4.00

    3/31/26 8:12:24 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    SEC Filings

    View All

    Heartbeam Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - HeartBeam, Inc. (0001779372) (Filer)

    7/2/26 4:15:31 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Heartbeam Inc.

    DEFA14A - HeartBeam, Inc. (0001779372) (Filer)

    6/25/26 8:30:01 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Heartbeam Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - HeartBeam, Inc. (0001779372) (Filer)

    6/24/26 5:28:27 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Leadership Updates

    Live Leadership Updates

    View All

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

    Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

    5/5/25 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

    First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl

    12/16/24 8:31:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    10/25/23 4:01:55 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    8/28/23 4:26:34 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    6/2/23 2:36:13 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Financials

    Live finance-specific insights

    View All

    HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition

    Company will license its 3D ECG signal technology to established partners, moving beyond direct medical device sales Advancing toward heart attack detection as a key expansion of the platform Tailoring its technology to fit each market, while operating with a leaner, more focused structure Company to provide more details on strategy as part of Second Quarter 2026 conference call in August HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a reorganization to prioritize global market reach and capital efficiency while accelerating execution. The company has aligned its operation

    6/24/26 4:05:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2026, and will be providing updates on key strategic growth initiatives, including its limited commercial launch for arrhythmia assessment, and developments on its extended-wear patch, heart attack detection and AI initiatives. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answe

    4/30/26 8:31:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Reports Fourth Quarter and Full Year 2025 Results

    HeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment First Commercial Partner ClearCardio™ to Bring HeartBeam's 3D ECG Technology to High-Growth Preventive Cardiology Market First Patients Enrolled in Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Completed the First Working Prototype of an Extended-Wear 12-Lead ECG Patch Strategic Collaboration with the Icahn School of Medicine at Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. ET   HeartBeam, Inc. (NASDAQ:BEAT), a

    3/12/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care